Information
295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea
+82 2-2157-9062
-
-
Overview
- Summary
- Samyang Biopharm is a healthcare solutions partner that originated as Samyang Corporation's pharmaceutical division in 1995, building competitiveness in medical devices, pharmaceuticals, and new drug development. The company holds a global market share leadership in biodegradable sutures, establishing a strong international presence. It is an innovative enterprise focused on developing incrementally modified drugs and gene therapies based on advanced drug delivery system (DDS) technology. The company concentrates on developing high-value-added healthcare products to enhance patients' quality of life.Samyang Biopharm is a healthcare solutions partner that originated as Samyang Corporation's pharmaceutical division in 1995, building competitiveness in medical devices, pharmaceuticals, and new drug development. The company holds a global market share leadership in biodegradable sutures, establishing a strong international presence. It is an innovative enterprise focused on developing incrementally modified drugs and gene therapies based on advanced drug delivery system (DDS) technology. The company concentrates on developing high-value-added healthcare products to enhance patients' quality of life.
- Key Products/Technologies
- Medical Devices: Development and production capabilities for bioabsorbable surgical sutures (Trisorb®, Monosorb®, Monofast®, Neosorb®, Neosorb® Rapid, antibacterial sutures, barbed sutures).Medical Devices: Development and production capabilities for bioabsorbable surgical sutures (Trisorb®, Monosorb®, Monofast®, Neosorb®, Neosorb® Rapid, antibacterial sutures, barbed sutures).
- Medical Devices: Provision of absorbable hemostats (SurgiGuard®) based on oxidized regenerated cellulose technology and non-absorbable hemostatic dressings (Q-Guard®).Medical Devices: Provision of absorbable hemostats (SurgiGuard®) based on oxidized regenerated cellulose technology and non-absorbable hemostatic dressings (Q-Guard®).
- Medical Devices: Possession of technology for absorbable anti-adhesion agents (InterGuard®) and partially absorbable surgical meshes (Proflex®).Medical Devices: Possession of technology for absorbable anti-adhesion agents (InterGuard®) and partially absorbable surgical meshes (Proflex®).
- Medical Devices: Development and sales of knotless wound closure devices (Monofix®) for minimally invasive surgery and aesthetic medical products like lifting threads (Croquis®) and fillers (Lafullen®).Medical Devices: Development and sales of knotless wound closure devices (Monofix®) for minimally invasive surgery and aesthetic medical products like lifting threads (Croquis®) and fillers (Lafullen®).
- Pharmaceuticals: Development and production of anti-cancer drugs (Genexol® PM Injection, Nanoxel® M Injection) based on drug delivery systems (DDS).Pharmaceuticals: Development and production of anti-cancer drugs (Genexol® PM Injection, Nanoxel® M Injection) based on drug delivery systems (DDS).
- Pharmaceuticals: The world's first company to successfully mass-produce paclitaxel active pharmaceutical ingredient (API).Pharmaceuticals: The world's first company to successfully mass-produce paclitaxel active pharmaceutical ingredient (API).
- Pharmaceuticals: Expansion capabilities for incrementally modified drug (IMD) and cytotoxic anti-cancer drug pipelines.Pharmaceuticals: Expansion capabilities for incrementally modified drug (IMD) and cytotoxic anti-cancer drug pipelines.
- Gene Therapeutics: Development of innovative gene therapies utilizing the SENS™ platform technology (tissue-selective gene delivery system).Gene Therapeutics: Development of innovative gene therapies utilizing the SENS™ platform technology (tissue-selective gene delivery system).
- Gene Therapeutics: Research and development capabilities for nucleic acid-based therapeutic delivery technologies.Gene Therapeutics: Research and development capabilities for nucleic acid-based therapeutic delivery technologies.
- Core Technologies: Possession of proprietary bioabsorbable polymer synthesis and application technologies (e.g., PGA, PCL, PDS, PDO, PGCL, PPDO).Core Technologies: Possession of proprietary bioabsorbable polymer synthesis and application technologies (e.g., PGA, PCL, PDS, PDO, PGCL, PPDO).
- Core Technologies: Development and application of drug delivery system (DDS) technologies using polymer nanotechnology (Polymeric Micelle (PM), Polymeric Nanoparticle (PNP), Sustained Release (SR), Transdermal Drug Delivery System (TDDS)).Core Technologies: Development and application of drug delivery system (DDS) technologies using polymer nanotechnology (Polymeric Micelle (PM), Polymeric Nanoparticle (PNP), Sustained Release (SR), Transdermal Drug Delivery System (TDDS)).
- Core Advantages
- Global market leader in biodegradable surgical suture raw materials, securing over 50% market share worldwide.Global market leader in biodegradable surgical suture raw materials, securing over 50% market share worldwide.
- Establishment of high technological barriers through proprietary bioabsorbable polymer material development and manufacturing capabilities.Establishment of high technological barriers through proprietary bioabsorbable polymer material development and manufacturing capabilities.
- Ability to develop differentiated pharmaceuticals and gene therapies through unique drug delivery system (DDS) platforms (PM, PNP, SENS™).Ability to develop differentiated pharmaceuticals and gene therapies through unique drug delivery system (DDS) platforms (PM, PNP, SENS™).
- Possession of EU and JGMP certified cytotoxic anti-cancer injectable drug manufacturing facilities and world-class production capabilities.Possession of EU and JGMP certified cytotoxic anti-cancer injectable drug manufacturing facilities and world-class production capabilities.
- Provision of a comprehensive healthcare solution portfolio encompassing medical devices, pharmaceuticals, and gene therapies.Provision of a comprehensive healthcare solution portfolio encompassing medical devices, pharmaceuticals, and gene therapies.
- Adherence to strict global quality systems and acquisition of certifications such as US FDA approval and CE Mark.Adherence to strict global quality systems and acquisition of certifications such as US FDA approval and CE Mark.
- Continuous expansion of product portfolio into medical aesthetics and minimally invasive surgery fields, aiming for market leadership.Continuous expansion of product portfolio into medical aesthetics and minimally invasive surgery fields, aiming for market leadership.
- Strengthening technological competitiveness through continuous R&D investment and certification as an innovative pharmaceutical company.Strengthening technological competitiveness through continuous R&D investment and certification as an innovative pharmaceutical company.
- Target Industrie
- Medical device manufacturing industry.Medical device manufacturing industry.
- Pharmaceutical and biotechnology industries (development and production of anti-cancer drugs, incrementally modified drugs, gene therapies).Pharmaceutical and biotechnology industries (development and production of anti-cancer drugs, incrementally modified drugs, gene therapies).
- Surgical fields (suturing, hemostasis, adhesion prevention, etc.).Surgical fields (suturing, hemostasis, adhesion prevention, etc.).
- Medical aesthetics industry (lifting threads, fillers, etc.).Medical aesthetics industry (lifting threads, fillers, etc.).
- Wound management and regenerative medicine fields.Wound management and regenerative medicine fields.
- Major Markets
- South Korea, China, Japan, Taiwan, India, Southeast AsiaSouth Korea, China, Japan, Taiwan, India, Southeast Asia
- Europe (general), Germany, HungaryEurope (general), Germany, Hungary
- United StatesUnited States
- Certifications/Patents
- Certifications: Acquisition of ISO 13485 (Medical Devices Quality Management System) certification.Certifications: Acquisition of ISO 13485 (Medical Devices Quality Management System) certification.
- Certifications: US FDA approval (Surgisorb® sutures, biodegradable polymer materials, ORC technology) and CE Mark acquisition.Certifications: US FDA approval (Surgisorb® sutures, biodegradable polymer materials, ORC technology) and CE Mark acquisition.
- Certifications: Operation of a global-standard quality management system through EU GMP and JGMP certifications (anti-cancer injectable drug factory, API production facilities).Certifications: Operation of a global-standard quality management system through EU GMP and JGMP certifications (anti-cancer injectable drug factory, API production facilities).
- Certifications: Compliance with KGMP (Korean Good Manufacturing Practice).Certifications: Compliance with KGMP (Korean Good Manufacturing Practice).
- Certifications: Designation as an Innovative Pharmaceutical Company by the Ministry of Health and Welfare and acquisition of LMO research facility certification.Certifications: Designation as an Innovative Pharmaceutical Company by the Ministry of Health and Welfare and acquisition of LMO research facility certification.
- Patents: Possession of numerous patents related to proprietary bioabsorbable polymer manufacturing technology.Patents: Possession of numerous patents related to proprietary bioabsorbable polymer manufacturing technology.
- Patents: Patents related to oxidized regenerated cellulose technology and partially absorbable surgical mesh Proflex®.Patents: Patents related to oxidized regenerated cellulose technology and partially absorbable surgical mesh Proflex®.
- Patents: Securing patents for polymer synthesis, manufacturing processes, and application fields of drug delivery systems (DDS).Patents: Securing patents for polymer synthesis, manufacturing processes, and application fields of drug delivery systems (DDS).
- Patents: Patents related to anti-cancer drugs, including novel compounds and formulation technologies.Patents: Patents related to anti-cancer drugs, including novel compounds and formulation technologies.
- Patents: Ownership of 596 patent documents (applications and grants), 239 patent families, and 21 granted patents.Patents: Ownership of 596 patent documents (applications and grants), 239 patent families, and 21 granted patents.
Introduction
Location
295 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea
클릭하여 위치 살펴보기
